Ingalls & Snyder LLC Myriad Genetics Inc Transaction History

Ingalls & Snyder LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 31, 2020	SELL	$10.69 - $16.49 $140,947 - $217,420	-13,185 Closed	0 $0
Q1 2020 Apr 22, 2020	SELL	$9.78 - $29.53 $143,462 - $433,175	-14,669 Reduced 52.66%	13,185 $189,000
Q4 2019 Jan 15, 2020	SELL	$20.93 - $35.1 $378,309 - $634,432	-18,075 Reduced 39.35%	27,854 $758,000
Q3 2019 Oct 16, 2019	SELL	$22.08 - $47.08 $84,213 - $179,563	-3,814 Reduced 7.67%	45,929 $1.32 Million
Q2 2019 Jul 11, 2019	SELL	$22.67 - $35.0 $68 - $105	-3 Reduced 0.01%	49,743 $1.38 Million
Q1 2019 Apr 11, 2019	BUY	$26.93 - $34.7 $5,924 - $7,634	220 Added 0.44%	49,746 $1.65 Million
Q4 2018 Jan 24, 2019	BUY	$27.23 - $45.56 $16,474 - $27,563	605 Added 1.24%	49,526 $1.44 Million
Q3 2018 Oct 24, 2018	SELL	$37.57 - $50.34 $4,696 - $6,292	-125 Reduced 0.25%	48,921 $2.25 Million
Q2 2018 Aug 10, 2018	SELL	$27.75 - $40.17 $1,470 - $2,129	-53 Reduced 0.11%	49,046 $1.83 Million
Q4 2017 Jan 19, 2018	SELL	$28.45 - $37.14 $128,025 - $167,130	-4,500 Reduced 8.4%	49,099 $1.69 Million
Q3 2017 Oct 20, 2017	BUY	$24.01 - $36.2 $1.29 Million - $1.94 Million	53,599	53,599 $1.94 Million

253

90.9M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.25B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.